This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lesiuk, H. Articles by Saunders, J. Search for Related Content PubMed PubMed Citation Articles by Lesiuk, H. Articles by Saunders, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Stroke, Vol 22, 896-901, Copyright © 1991 by American Heart Association

ARTICLES

Effect of U74006F on forebrain ischemia in rats

H Lesiuk, G Sutherland, J Peeling, K Butler and J Saunders
Department of Surgery, University of Manitoba, Canada.

We examined the effect of a putative lipid peroxidation inhibitor, the 21-aminosteroid U74006F, on transient forebrain ischemia in rats. Acute- treatment rats received either 3 mg/kg U74006F (n = 7) or carrier vehicle (n = 5) intravenously 30 minutes before ischemia, sustained- treatment rats received the same treatment before ischemia followed by 3 mg/kg U74006F (n = 6) or carrier vehicle (n = 5) intraperitoneally every 6 hours for 48 hours, and control rats (n = 7) received no injection. Coronal magnetic resonance images were obtained daily for 3 days, followed by the histological examination of perfusion-fixed brains. Control rats demonstrated magnetic resonance image changes indicative of neuronal damage in the striatum at 24 hours postischemia, followed by changes in the hippocampus and neocortex at 48 hours. No significant effect of U74006F treatment on striatal or hippocampal injury was demonstrated. However, both the acute and sustained U74006F treatments produced a significant reduction in the severity of neuronal damage in the neocortex (p less than 0.05). Our results suggest that U74006F is of benefit in ameliorating ischemic neuronal injury, particularly in the neocortex, and raise the possibility of regional variability in lipid peroxidation following an ischemic insult.

This article has been cited by other articles:

				R. J. Kavanagh and P. C. A. Kam Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection Br. J. Anaesth., January 1, 2001; 86(1): 110 - 119. [Abstract] [Full Text] [PDF]

				Tirilazad Mesylate in Acute Ischemic Stroke : A Systematic Review Stroke, September 1, 2000; 31(9): 2257 - 2265. [Abstract] [Full Text] [PDF]

				R. F. Villa and A. Gorini Pharmacology of Lazaroids and Brain Energy Metabolism: A Review Pharmacol. Rev., March 1, 1997; 49(1): 99 - 136. [Abstract] [Full Text] [PDF]

				H. Kim, R. C. Koehler, P. D. Hurn, E. D. Hall, and R. J. Traystman Amelioration of Impaired Cerebral Metabolism After Severe Acidotic Ischemia by Tirilazad Posttreatment in Dogs Stroke, January 1, 1996; 27(1): 114 - 121. [Abstract] [Full Text]

				M. D. Ginsberg Review : Neuroprotection in Brain Ischemia: An Update (Part II Neuroscientist, May 1, 1995; 1(3): 164 - 175. [Abstract] [PDF]